Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative

JAMA

Volumn 292, Issue 16, 2004, Pages 1983-1988

  Majumdar, Sumit R ^a   Almasi, Elizabeth A ^b   Stafford, Randall S ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ESTROGEN PLUS PROGESTIN; GESTAGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONSUMER; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; FEMALE; HEALTH HAZARD; HEALTH PROMOTION; HEALTH STATUS; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; WOMEN HEALTH INITIATIVE;

EID: 6944239947     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.16.1983     Document Type: Article

References (28)

1. Ross-Degnan D, Soumerai SB, Fortess EE, Gurwitz JH. Examining product risk in context: market withdrawal of zomepirac as a case study. JAMA. 1993;270:1937-1942.
2. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA. 2000;284:3036-3039.
3. Stafford RS, Radley DC. National trends in anti-obesity medication use. Arch Intern Med. 2003;163:1046-1050.
4. Majumdar SR, Inui TS, Gurwitz JH, et al. Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction. J Gen Intern Med. 2001;16:351-359.
5. Stafford RS, Furberg CD, Finkelstein SN, et al. Impact of clinical trial results on national trends in α-blocker prescribing, 1996-2002. JAMA. 2004;291:54-62.
6. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53.
7. Naylor CD. The complex world of prescribing behavior. JAMA. 2004;291:104-106.
8. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73:4-8.
9. Wang TJ, Ausiello JC, Stafford RS. Trends in antihypertensive drug advertising, 1985-1996. Circulation. 1999;99:2055-2057.
10. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373-380.
11. Majumdar SR, McAlister FA, Soumerai SB. Synergy between publication and promotion: comparing adoption of new evidence in Canada, and the United States. Am J Med. 2003;115:467-472.
12. Levy R. The role and value of pharmaceutical marketing. Arch Fam Med. 1994;3:327-332.
13. Holmer AF. Industry strongly supports continuing medical education. JAMA. 2001;285:2012-2014.
14. Peterson M. Survey halted, drug makers seek to protect hormone sales. New York Times. July 17, 2002: C1.
15. Herrington DM, Howard TD. From presumed benefit to potential harm: hormone therapy and heart disease. N Engl J Med. 2003;349:519-521.
16. Ma J, Stafford RS, Cockburn IM, Finkelstein SN. A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clin Ther. 2003;25:1503-1517.
17. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
18. Schwartz LM, Woloshin S. The media matter: a call for straightforward medical reporting. Ann Intern Med. 2004;140:226-228.
19. North American Menopause Society. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause. 2003;10:6-12.
20. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
21. Katz A. Observations and advertising: controversies in the prescribing of hormone replacement therapy. Health Care Women Int. 2003;24:927-939.
22. Gardner J. When a brand name gets hit by bad news. US News World Rep. November 1992;8:71.
23. Zate M. Two words you won't see: apologize, regret. Ventura County Star. August 26, 2000:D01.
24. Damage control. AdWeek [Western ed]. November 25, 1996;46:3.
25. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA. 2001;285:2009-2012.
26. Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative. JAMA. 2003;289:3241-3242.
27. Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. BMJ. 2003;327:845-846.
28. Mukherjee D, Nissen S, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.